Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Abstract Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term surviv...

Full description

Bibliographic Details
Main Authors: Tomomi Masuda, Noriaki Sunaga, Norimitsu Kasahara, Kazutaka Takehara, Masakiyo Yatomi, Kenichiro Hara, Yasuhiko Koga, Toshitaka Maeno, Takeshi Hisada
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Thoracic Cancer
Subjects:
Afatinib
non‐small cell lung cancer
rechallenge
uncommon EGFR mutation
Online Access:https://doi.org/10.1111/1759-7714.13532

Internet

https://doi.org/10.1111/1759-7714.13532

Similar Items